Objective
to report the clinical 2-year outcome of a combination of ticagrelor and aspirin for 1 month, followed by ticagrelor for 23 months compared to standard DAPT for 12 months (aspirin plus clopidogrel or ticagrelor) followed by another 12 months aspirin alone
Study
randomised, open-label, multicentre superiority trial
Population
patients with stable CAD or ACS
Endpoints
composite of all-cause death or new Qwave MI at 24 months; secondary safety endpoint: bleeding BARC grade 3 to 5
Conclusion
treatment with ticagrelor plus aspirin (1 month) followed by ticagrelor for 23 months was not superior to standard DAPT (12 months) followed by another 12 months of aspirin treatment
Vrankx et al. Lancet. 2018;392:940-9
